Core Viewpoint - Binhai Investment (02886) announced the acquisition of Hegia, a pioneer in siRNA drug development, for a maximum base price of RMB 12 million, which will enhance the company's innovation in chronic disease management and clinical advancement [1][2]. Group 1: Acquisition Details - The acquisition involves Binhai Investment's wholly-owned subsidiary, Chengda Pharmaceutical Investment (Beijing) Co., Ltd., purchasing 100% of Hegia's shares, with part of the payment in cash and part in shares [1]. - Hegia will become an indirect wholly-owned subsidiary of Binhai Investment upon completion of the acquisition [1]. Group 2: Hegia's Technology and Market Potential - Hegia specializes in siRNA technology, which addresses limitations in existing chronic disease therapies, with a projected global transaction volume in the siRNA field exceeding USD 35 billion by 2025, reflecting a growth rate of over 40% [2]. - Hegia has developed a differentiated delivery platform with proprietary technology, including the MVIP platform for long-acting liver-targeted delivery, which addresses patient compliance issues in chronic disease treatment [3]. Group 3: Clinical Assets and Pipeline - Hegia possesses four clinical-stage assets and over ten preclinical assets, all with first-in-class and best-in-class potential [4]. - Key clinical assets include Kylo-11, a long-acting siRNA for treating elevated lipoprotein(a) levels, currently in Phase II trials, and Kylo-12, targeting high triglycerides, expected to start Phase II trials in mid-2026 [5][6].
滨海投资(02886)拟最高基础代价1200万元收购赫吉亚100%股权 携手加快siRNA肝外递送平台的开发